Subjects presenting with probable acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study. Consented subjects will be randomized to receive ticagrelor started with a loading dose immediately after enrollment versus receiving a loading dose of ticagrelor during cardiac catheterization after diagnostic angiography but prior to stenting. Optical coherence tomography (OCT) will be performed after stenting and the volume of thrombus within the new stent will be measured and compared between the groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
SINGLE
Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
Massachusetts General Hospital
Boston, Massachusetts, United States
Total thrombus burden as measured by the volume of in-stent thrombus quantified by planimetry.
The total thrombus burden measured on OCT images will be assessed. The volume of in-stent thrombus will be quantified by planimetry.
Time frame: Thrombus burden will be measured at the end of the coronary artery stenting procedure.
PRI (platelet reactivity index) as measured bu the PLT-VASP assay.
The extent of platelet inhibition will be measured by PLT-VASP and VerifyNow P2Y12 assays.
Time frame: PRI iwill be measured at the time of OCT image acquisition.
P2Y12 Reaction Units as measured by the VerifyNow P2Y12 assay.
The extent of platelet inhibition will be measured by PLT-VASP and VerifyNow P2Y12 assays.
Time frame: P2Y12 will be measured at the time of OCT image acquisition.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.